SEC 10-Q

PharmaCyte Biotech reports $0 in revenue, $0.5M net loss, and no clinical progress in 10-Q, signaling critical funding and operational crisis

PharmaCyte Biotech's latest 10-Q reveals a company in a state of clinical and financial stasis. The core finding is the absence of revenue and the failure to advance its lead pancreatic cancer therapy into clinical trials, a critical milestone repeatedly deferred. The financials show a consistent cash burn with no offsetting income, leading to a precarious liquidity position of approximately $2.1 million. The filing explicitly states dependence on raising additional capital, signaling a high probability of a dilutive equity offering, debt, or a strategic transaction in the near term. The operational update confirms no trial initiation, which is a significant negative catalyst for a clinical-stage biotech. This lack of progress suggests underlying issues with the Cell-in-a-Box® technology, regulatory submissions, or manufacturing. For investors, this represents a 'show me' story that has failed to show. The primary path to shareholder value is now a binary event: securing non-dilutive funding or achieving a sudden clinical milestone, both of which appear low-probability based on the disclosed information.

Ticker

PMCB

Form

10-Q